Condition
Early Allograft Dysfunction
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
150%
3 of 2 completed with results
Key Signals
3 with results67% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 2 (1)
Trial Status
Completed2
Unknown1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03031470Phase 2Terminated
Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation
NCT04203004Not ApplicableUnknown
HOPE With Cytokine Filtration in Liver Transplantation (Cyto-HOPE)
NCT02798861Completed
Controlled Attenuation Parameter (CAP) in Liver Allografts
NCT01887171Not ApplicableCompletedPrimary
Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus
Showing all 4 trials